Iowa Patent of the Month – November 2024
NanoMedTrix, LLC has unveiled a groundbreaking innovation in targeted cancer treatment with their mesoporous silica nanoparticle (MSN) technology. This invention offers a precise, non-invasive method for delivering chemotherapy drugs directly to tumors while minimizing systemic exposure and side effects. Encased in a polymeric enteric coating, these nanoparticles ensure the bioactive agents are released only at the intended site, bypassing the stomach’s acidic environment for maximum efficacy.
What sets this platform apart is its dual capability: targeted drug delivery and advanced imaging. The MSNs are functionalized with contrast agents detectable via MRI, CT, ultrasound, or fluorescence, enabling real-time monitoring of tumor response. This fusion of therapy and diagnostics, or “theranostics,” offers clinicians unprecedented control and insight into treatment effectiveness.
A hallmark of this technology is its adaptability. By incorporating different chemotherapeutic agents—such as gemcitabine, mitomycin-c, or docetaxel—and linking them to cancer-specific peptides like Cyc6, NanoMedTrix’s invention can be customized for personalized medicine. This is particularly significant for conditions like bladder cancer, where variability in patient response often challenges traditional treatments.
Preclinical models have demonstrated the platform’s potential, showing sustained tumor suppression and reduced recurrence. The precision delivery mechanism also allows for the combination of multiple therapeutic agents in a single formulation, addressing both invasive and non-invasive tumors simultaneously. Moreover, the real-time imaging capabilities enhance safety and effectiveness, ensuring each treatment is tailored to the patient’s unique needs.
NanoMedTrix’s innovation promises to revolutionize oncology by enhancing drug efficacy, reducing side effects, and empowering personalized cancer care. With this novel approach, they are not just advancing nanomedicine—they are redefining the future of cancer treatment.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
